Suraksha Diagnostic Ltd

Suraksha Diagnostic Limited: Trading window closed from 01 October 2026 until 48 hours after the declaration of unaudited standalone and consolidated financial results for the quarter and half-year ended 30 September 2026.

AGM Details

• AGM held on 22 September 2026 at 11:30 a.m. IST via VC/OAVM.
• Record date for voting rights: 15 September 2026.

Resolutions & Voting Outcomes

• Ordinary: Adopt standalone financial statements; 99.9989% in favour.
• Ordinary: Adopt consolidated financial statements; 99.9990% in favour.
• Ordinary: Declare final dividend of Rs 0.50 per equity share.
• Ordinary: Reappoint Satish Kumar Verma as director (non-exec, non-independent).
• Ordinary: Ratify remuneration of Cost Auditor for FY2027; approved.

Dividend

• Final dividend of Rs 0.50 per equity share approved.

Director Changes

• Satish Kumar Verma reappointed as director, non-exec non-independent.

Auditors / Remuneration

• Remuneration for Cost Auditor for FY2027 ratified.

AGM Details

• Held on 22 September 2026 at 11:30 IST via VC/OAVM.
• No physical meeting; proxies not applicable.

Key Resolutions

• Adoption of standalone financial statements for FY ended 31 Mar 2026.
• Adoption of consolidated financial statements for FY ended 31 Mar 2026.
• Final dividend of ₹0.50 per equity share (₹2 face), 25%.
• Re-appointment of Satish Kumar Verma as Director (retiring by rotation) – Special Business.
• Ratification of remuneration payable to Cost Auditor for FY ending 31 Mar 2027.

Voting Outcome

• All resolutions passed by requisite majority.
• Standalone financials: Passed.
• Consolidated financials: Passed.
• Dividend: Passed.
• Director re-appointment: Passed.
• Cost Auditor: Passed.

Dividend Details

• Final dividend of ₹0.50 per equity share for FY2025-26.

Director Changes

• Satish Kumar Verma re-appointed as Director (Non-Executive Non-Independent).

Auditor Appointments

• Cost Auditor remuneration ratified for FY ending 31 March 2027; M/s S. Chhaparia & Associates.

AGM details

• Held 22 September 2026 at 11:30 A.M. via VC/OAVM.

Key resolutions

• Ordinary: Adopt standalone financial statements for year ended 31 March 2026.
• Ordinary: Adopt consolidated financial statements for year ended 31 March 2026.
• Ordinary: Declare final dividend of ₹0.50 per equity share.
• Ordinary: Re-appoint Satish Kumar Verma, retires by rotation.
• Special: Ratify remuneration payable to Cost Auditor for FY ending 31 March 2027.

Dividend

• Final dividend of ₹0.50 per equity share approved.

Director changes

• Satish Kumar Verma to be re-appointed by rotation.

Auditor updates

• Cost auditor remuneration ratified for FY ending 31 March 2027.

Voting results

• All resolutions passed by requisite majority.

AGM details

• AGM scheduled for 22 September 2026 at 11:30 IST via VC/OAVM.
• Record date for dividend: 15 September 2026.
• Cut-off date for e-voting: 15 September 2026; remote e-voting 18 September 2026 to 21 September 2026.
• Soft copy of Annual Report and AGM Notice available on Suraksha website.
• Also available on BSE/NSE and NSDL websites.
• Annual Report and AGM Notice emailed to shareholders with registered addresses.
• KYC details update requested if not registered with DP.

Financial highlights

• FY26 revenue from operations: ₹310.41 crores.
• EBITDA: ₹98.60 crores; EBITDA margin 31.8%.
• PAT: ₹31.40 crores; PAT margin 10.1%.
• EPS: ₹6.18 (basic and diluted).
• Patients served: 1.37 million; tests conducted: 8.16 million.
• Revenue per patient: ₹2,264; tests per patient: 6.
• ROE: 14.11%; net debt to equity: 0.41x.
• Network: 68 centres, 193 collection centres, 8 laboratories.
• Average revenue per centre: ₹45.65 Lakhs.

Operations & network

• Hub-and-spoke model supports broad Eastern/North-Eastern reach.
• Average revenue per centre reported at ₹45.65 Lakhs.
• 8 laboratories; 1 central reference lab; CAP-accredited labs.
• Present footprint: 68 diagnostic centres across region; 1 central lab.
• Pathology share ~49%, Radiology ~44%, Doctor consultations ~7% of revenue.

Genomics & technology

• Launched Suraksha Genomics; Eastern India's first comprehensive genomics hub.
• Acquired 63% stake in Fetomat Wellness Private Limited; consolidation completed 9 Apr 2025.
• Genexus platform introduced; oncology reporting 48-72 hours.
• CAP accreditation renewed across pathology operations.

Strategic acquisitions & partnerships

• Fetomat Wellness Private Limited acquired; foetal/maternal medicine capabilities expanded.
• Genomics vertical strengthens prenatal/inherited disease testing; pharmacogenomics and oncology panels.
• Management aims to further expand genomics capabilities in high-value diagnostics.

Dividend & equity incentives

• Dividend proposed: ₹0.50 per equity share (25% of face value).
• Record date: 15 Sep 2026; dividend paid within 30 days post AGM.
• ESOP 2024: 208,164 options granted; 163,549 outstanding; exercise price ₹228.

Governance & risk

• Board: 7 directors; 4 Independent; 2 Executive; 1 Non-Executive Non-Independent.
• Arun Sadhanandham resigned 6 Jun 2025; CFO Ravindra ceased 31 May 2026.
• Auditors: M S K A & Associates LLP (converted to LLP in 2026).
• Internal controls deemed adequate; no material weaknesses observed.

CSR & ESG

• CSR expenditure ₹61.08 lakh; 2 CSR Committee meetings in FY26.
• CSR policy aligned with Schedule VII; details on company website.
• ESG disclosures not required under BRSR due to market cap status.

Outlook & risks

• Diagnostics industry in India projected to grow ~12% CAGR over next five years.
• Expansion risks include pre-operative costs, utilization ramp-up, and margin pressure.
• Geographic concentration in East/NE exposes regional risk and regulatory shifts.

Financial Performance

• Q1 FY27 total income INR 887 million; YoY growth 21%.
• EBITDA INR 315 million; margin 36% vs 34% in Q1 FY26.
• PAT INR 128 million; margin 14.7%; YoY growth 40%.
• Patients served 0.38 million; tests performed 2.10 million; tests per patient 5.56.
• Revenue per patient INR 2,321; EBITDA per patient Rs. 835.
• Network at 72 centres; added 1 hub and 3 spokes in Q1.
• Mature centres EBITDA margin 40.9%; centres <2 years profitable at 6.5% from -5.5% last quarter.

Operations & Genomics

• Genomics revenue Rs 13.7 million; up 136% YoY; five quarters of sequential growth.
• Genomics focus areas include prenatal, inherited diseases, pharmacogenomics, oncology panels; AI/genome testing in pipeline.
• Alzheimer’s blood test launched; AI MRI early-detection project with CSIR.
• Q1: one hub and three spokes commissioned; July–Aug adds two hubs and three spokes.
• Jharkhand hub commissioned; Tripura hub planned; throughput/utilization focus; centralized procurement for cost efficiencies.
• Genomics margins 15–20%; Genomics is 80% B2C and 20% B2B.

Guidance and Outlook

• FY27 EBITDA margin floor not below 34%.
• Genomics growth trajectory around 20% quarterly growth for FY27.
• Capex outlook around Rs 70–80 crores in FY27.
• On track to open 100 centres by FY28.

Q&A Highlights

• Margin expansion driven by volume and operating leverage; mature centers expected to sustain margins.
• Spoke vs hub expansion: capex light; ongoing center mix to support growth.
• Genomics capex spent around Rs 22 crore over 3 years; mature genomic labs turnover benchmark Rs 100–250 crore.
• Break-even: spoke centers 3–4 months; HO level 8–9 months.
• Geography: Jharkhand hub already open; Tripura slated; Greater Kolkata has nine hubs; potential to double.
• Test volume growth around 10–11% in Q1; mix improvement contributing to per-test uplift.